GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » E10

ValiRx (LSE:VAL) E10 : £-7.84 (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ValiRx's adjusted earnings per share data for the fiscal year that ended in Dec. 2022 was £-0.031. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is £-7.84 for the trailing ten years ended in Dec. 2022.

During the past 3 years, the average E10 Growth Rate was 6.80% per year. During the past 5 years, the average E10 Growth Rate was 37.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of ValiRx was 62.50% per year. The lowest was 6.80% per year. And the median was 48.60% per year.

As of today (2024-04-25), ValiRx's current stock price is £ 0.0345. ValiRx's E10 for the fiscal year that ended in Dec. 2022 was £-7.84. ValiRx's Shiller PE Ratio of today is .


ValiRx E10 Historical Data

The historical data trend for ValiRx's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx E10 Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.11 -9.68 -11.63 -10.31 -7.84

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -10.31 - -7.84 -

Competitive Comparison of ValiRx's E10

For the Biotechnology subindustry, ValiRx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ValiRx's Shiller PE Ratio falls into.



ValiRx E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ValiRx's adjusted earnings per share data for the fiscal year that ended in Dec. 2022 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-0.031/125.3000*125.3000
=-0.031

Current CPI (Dec. 2022) = 125.3000.

ValiRx Annual Data

per_share_eps CPI Adj_EPS
201312 -23.438 99.200 -29.605
201412 -16.850 99.900 -21.134
201512 -8.325 100.400 -10.390
201612 -10.275 102.200 -12.597
201712 -2.375 105.000 -2.834
201812 -1.175 107.100 -1.375
201912 -0.331 108.500 -0.382
202012 -0.038 109.400 -0.044
202112 -0.023 114.700 -0.025
202212 -0.031 125.300 -0.031

Add all the adjusted EPS together and divide 10 will get our e10.


ValiRx  (LSE:VAL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ValiRx E10 Related Terms

Thank you for viewing the detailed overview of ValiRx's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines

From GuruFocus

Valaris to Present at Fearnley Securities' Offshore Drilling Seminar

By Business Wire Business Wire 01-10-2023

Valaris Provides Quarterly Fleet Status Report

By Business Wire Business Wire 10-31-2022

Valaris Provides Fleet Status Report

By Business Wire Business Wire 05-02-2023

Valaris Announces Contract Awards and Fleet Status Updates

By Business Wire Business Wire 12-16-2022

Valaris Publishes Sustainability Report

By Business Wire Business Wire 12-15-2022

Valaris Announces Contract Award for Drillship VALARIS DS-12

By Business Wire Business Wire 11-21-2022